Liton Rx offering is now closed and is no longer accepting investments.


Digital solution to your prescription

We believe our healthcare and pharmacy model is broken. Join in our mission to make healthcare and pharmacy affordable and convenient. At LitonRx, we believe in solving this by focusing on the 3 C's of Care, Convenience and Cost through digital enablement. LitonRx offers an affordable digital pharmacy and subscription based concierge virtual care services. Our product, LitonMD, is currently in development and will be coming soon to the market.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Liton Rx

$128,748.50 Raised

Reasons to Invest

  • In our view, the current delivery and pharmacy model is broken, and we believe that healthcare needs to be affordable and convenient. 

  • We’ve designed contemporary digital health and prescription services that address key issues including price transparency, convenience and affordability. We provide concierge Physician and Medications on a low monthly subscription model.

  • Healthcare is approximately 20% of US GDP (source). The pharmaceuticals market is estimated to grow from $336 Billion to potentially $505 Billion by 2023 across developed markets (source). We see this as a hot space and consumers are adopting digital health services much faster post COVID.


Redefining the pharmacy experience


We’re in a new era in digital health, and to us, that means filling prescriptions shouldn’t be a hassle. At LitonRx, we provide a fast, affordable, digital alternative to waiting in line at the pharmacy. Through our subscription-based virtual concierge care and pharmacy fulfillment services, we offer free same-day delivery of covered formulary prescription medications. With Providers and Pharmacists just a click away, we help save time and money for those seeking care. LitonMD, is a product sub-brand of LitonRX. LitonMD is currently in development and expected to launch to the market soon.

We consider ourselves a digital health and pharmacy with a heartbeat. Our mission is to provide price transparency, improve medication access and adherence, and empower our community for better healthcare. With this, we thrive on our connection with providers, pharmacists and patients, and unlike competition, we aim to put patients at the center of our approach.

The Problem & our Solution

We believe to be disrupting a fragmented Pharma market with care, convenience, and cost


In today’s challenges, we see the inverse relationship of increasing cost and lower health outcomes through difficulty with access to medications, and a lack of price transparency, education, and communication between Pharma and Providers.

As a digital health service, we believe LitonRx brings these proximities closer to better healthcare through our cost-effective model and concierge service, LitonMD. 

Care: Delivering 24/7 virtual concierge care to patients - digitally keeping pharmacists in touch.

Convenience: Full preauthorization support, with same-day home delivery

Cost: Transparent and affordable monthly subscription and formulary pricing - including a competitor's price match guarantee

Our monthly subscription model for LitonMD is $75 a month (50% margin), and that along with retail sales are the two key sources of revenue.

The Market & Our Traction

In 2020, Pharmacy spending nearly doubled (source)

With that, it makes sense that the market is estimated to grow from $336 billion to potentially $505 Billion by 2023 across developed markets (source). 

Because we focus on the connection between pharmacists, providers, and those seeking care - we feel we have huge market potential with little competition. When it comes to our traction, we have...

  • Opened 4 pharmacy locations 
  • Granted patients access to our provider network to deliver 24/7 virtual care 
  • Expanded licensing to provide pharmacy services to 5 states

And we are anticipating...

  • Nationwide services by Q1 2023
  • Launching LitonMD services Q4 2022

why invest

We believe the LitonRx solution impacts every touchpoint - a potential win for all stakeholders

We believe to be entering a hot space with a growing market and clear digital needs. To us, it is apparent that there is an increase in consumers that are seeking and adopting digital health services for convenience and immediate attention to their needs. In our view, LitonRx is on track for growth and is anticipated to expand in an additional 31 states by the end of the calendar year. 

Overall, our digital technology aims to streamline the prescription process for patients, providers, and payers, making it a win-win for everyone involved. Invest today, and help us build a future of more accessible, transparent digital care.

Bold (⌘B)



2080 N Dobson Road # 3
Chandler, AZ 85226


We believe our healthcare and pharmacy model is broken. Join in our mission to make healthcare and pharmacy affordable and convenient. At LitonRx, we believe in solving this by focusing on the 3 C's of Care, Convenience and Cost through digital enablement. LitonRx offers an affordable digital pharmacy and subscription based concierge virtual care services. Our product, LitonMD, is currently in development and will be coming soon to the market.


Kishlay Anand
Kishlay Anand
CEO & President

Experienced and Visionary Healthcare leader with passion for Innovation. 

Founder and President of Apricus Health, an innovative tech enabled value based services organization which aligns 3 P’s in Healthcare; Physicians, Payors and Patients.

Founder and CEO 

AKOS,, is an innovative value based integrated care delivery platform with significant ROI for Employers with decreased medical costs, early return to work, lower premiums and timely care for their employees.

Currently, Mr Anand spent approximately 80% of his time focusing on the company and 20% of his time focusing on his other businesses. Please refer to our risk factors and the Directors & Officers section of our offering materials for further details.

Pankaj Jain
Pankaj Jain
Co-Founder, Treasurer, Director, Advisor (Part-Time)

Dr. Pankaj Jain MD, F.A.A.P, F.A.C.C, is a compassionate physician, visionary entrepreneur and philanthropist. He is a double board-certified Pediatrician and Pediatric Cardiologist.

Dr. Jain has an extensive experience in medical field working in multiple countries (India, U.A.E., Canada and US) for over 20 years, which makes him a distinguished physician. Dr. Jain is an emerging entrepreneur, and gained valuable experience in business by investing in multiple small businesses and startups. Additionally, he provides advice in his family’s overseas business operations, now in its third generation of business. Dr. Jain is humanitarian, committed to uplifting society. He also participates in multiple charity health camps to provide awareness and medical care to unprivileged society.

Ravi Juvvala

Ravi Juvvala

Chief Technology Officer (Part-Time)

Ravi is a technology architect who builds and manages enterprise solutions. He is a business-focused technology leader with a successful history of leveraging technology to drive innovation and growth. From startups to the most established global companies, he is experienced at driving and managing change while generating improvements in top line revenue, operational efficiencies and competitive advantage. Ravi brings 20+ years of expertise leading and architecting cloud solutions, AI, data analytics, and machine learning for various Fortune 500 clients.

Tim Whalen

Tim Whalen

Director of Pharmacy Operations

Tim has over 25 years of experience in pharmacy management. He started his pharmacy career with Walgreens in 1997 with their management program while on break from his pharmacy studies at Broward College and Nova Southeastern University. He began his pharmacy management career in South Florida. Tim has also worked as a Regional Manager where he was responsible for multiple pharmacies across several states before joining LitonRx in October of 2020. 

Robin Hohenstern

Robin Hohenstern

Pharmacist in Charge

Robin graduated from North Dakota State University and has over 30 years experience as a pharmacist. She has worked in many different practice settings, but community pharmacy is her passion.


Liton Rx
Dec 23, 2022
Class A nonvoting commom stocks

Maximum Number of Shares Offered subject to adjustment for bonus shares



LitonRx, Inc.

Corporate Address


2080 N Dobson Road # 3, Chandler, AZ 85226

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


Class A nonvoting commom stocks

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



*Maximum number of shares offered subject to adjustment for bonus shares. See bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*


Friends and Family Early Birds

Invest $500 within the first 72 hours and receive 15% bonus shares.

Super Early Bird Bonus

Invest $500 within the first 6 days and receive 10% bonus shares.

Early Bird Bonus

Invest $500 within the first 9 days and receive 5% bonus shares.


$5,000+ | Tier 1

Invest $5,000+ and receive access to a private Facebook Group + 1% Bonus Shares.

$10,000+ | Tier 2

Invest $10,000+ and receive access to a private Facebook Group + 2% Bonus Shares.

$25,000+ | Tier 3

Invest $25,000+ and receive access to a private Facebook Group + 5% Bonus Shares.

$50,000+ | Tier 4

Invest $50,000+ and receive access to a private Facebook Group + 10% Bonus Shares.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Liton Rx will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 10 additional shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Any expense labeled “Travel and Entertainment”. Salary payments made to one’s self, a friend or relative.



LitonRx launches LitonMD, a NEW + AFFORDABLE Monthly Healthcare Subscription Plan!

We are thrilled to announce the launch of LitonMD, a NEW + AFFORDABLE monthly healthcare subscription plan that includes:

-Unlimited Virtual Doctor Visits
-Up to 3 Medications for Free
-Same-day Delivery of Prescriptions
-FREE app to schedule visits, refill prescriptions and more!

LitonMD empowers consumers to receive the care they deserve at their fingertips. We want everyone to be a part of our growing community and market disrupting service, so we welcome you to invest now!


Our Newest Location Is Now Open!

Here we grow again! We are excited to announce our newest LitonRx location in Flagstaff, Arizona. We are committed to serving the Flagstaff community with fast, convenient and affordable prescription delivery. With continued growth and new locations on the horizon, we continue to disrupt the digital pharmacy world and providing a hassle-free experience for consumers. 


LitonRX is growing!

Our team is growing! We are pleased to welcome Atul Kumar to the LitonRx team as Chief Development Officer. Atul has 20+ years of experience in market development, managing global client engagements for large-scale projects, programs, products, and P&L operations in the Healthcare, Pharmaceutical, and Life Sciences domain. He has a successful track record of incubating & mentoring global teams, inspiring trust, generating confidence, and developing alliances and collaborative partnerships. In his past roles, Atul has worked with MNCs like GE, Genpact, Infosys, Virtusa, and Infostretch.


Investors Update

We are excited to see our community come in and invest in Liton Rx. Our insiders have invested a total of $10000.00 into the offering to date. We hope you join in as well invest in LITON RX,


Liton Rx Team


120 K Raises in First Week !!


“ Last chance for Super early bird bonus ”

Don’t miss out on the last day to get  10% bonus shares in Liton Rx. Offer expires Thursday, 12 AM. We would love for you to be a part of our community!


Team Liton Rx


Liton Rx is offering Early Bird Perks!”

We are offering Perks for a limited amount of time! Invest in Liton Rx within the next 2 days to receive bonus shares.


We want everyone to be a part of our community, so invest now to receive bonus shares as a thank you for your early support in our journey.

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Liton Rx.


StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.


Tier 1

Invest $5,000+ and receive access to a private Facebook Group + 1% Bonus Shares.


Tier 2

Invest $10,000+ and receive access to a private Facebook Group + 2% Bonus Shares.


Tier 3

Invest $25,000+ and receive access to a private Facebook Group + 5% Bonus Shares.


Tier 4

Invest $50,000+ and receive access to a private Facebook Group + 10% Bonus Shares.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.